Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
OCT Clinical is a clinical trial CRO service provider whose website positions the company as “Managing Clinical Trials in Eastern Europe.” It states that it has provided high-quality CRO services since 2005, with a team of around 130 professionals, more than 300 completed clinical studies, coverage across 29 therapeutic areas, and operations in multiple European and related countries. Strictly speaking, it is not a standard SaaS or enterprise software product, but a clinical R&D outsourcing provider; the scraped website text discloses relatively little about its digital platform capabilities.
Its core service modules include clinical study design and preparation, medical writing, consulting and regulatory support, drug safety and pharmacovigilance, project management and monitoring, clinical data management, biostatistics, clinical supplies services, and logistics. Services cover Phase I–IV clinical trials and BE studies, and OCT Clinical can provide either full-service clinical research outsourcing or individual standalone services. Therapeutic areas include oncology, gastroenterology, rheumatology, infectious diseases, respiratory diseases, neurology, and more. It also emphasizes its “rescue study” capability: taking over trials that face recruitment, timeline, or execution bottlenecks and developing acceleration plans.
The website does not disclose standard packages, unit prices, or payment methods. Quotes are mainly obtained by submitting an RFP, booking a meeting, or contacting regional offices. In terms of free offerings, the only clearly mentioned option is a Free Feasibility Report; there is no free plan, trial version, or subscription-based SaaS pricing. There is also no visible information about third-party integrations, APIs, developer support, cloud deployment, or self-hosted deployment, so it should not be evaluated using the usual enterprise software procurement framework.
Its main strength is concentrated regional experience: it can reach 2,100 study sites, claims to have enrolled 58,937 patients, and says it can deliver EMA/FDA-acceptable data. One case study mentions that a Samsung Bioepis lung cancer study completed recruitment 7 months ahead of schedule. Its multilingual website includes Chinese content, which is helpful for international sponsors. The downside is limited public transparency: it does not disclose security certifications, data protection mechanisms, SLAs, system permissions, eClinical tool stack, or contract pricing. In addition, its operational focus is Eastern Europe and parts of Europe, Turkey, Brazil, and similar regions; its local execution capability in China is not clearly described.
OCT Clinical is better suited for pharmaceutical and biotechnology companies that need to run clinical trials in Eastern Europe, Central and Eastern Europe, or related countries, especially sponsors that prioritize patient recruitment speed, regulatory support, and full-process CRO delivery. Chinese companies planning overseas European clinical research could consider it as a regional CRO candidate. Its access status from China cannot be determined from the text alone, and payment methods are not disclosed. For local alternatives in China, companies could consider Tigermed, R&G PharmaStudies, or Fountain Medical; global alternatives include IQVIA, ICON, Parexel, PPD, and Medpace.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on oct-clinicaltrials.com official site.
oct-clinicaltrials.com is an Russia SaaS provider. TG4G tracks its product information, an overall rating of 7.0/10, and a China-accessibility score of Workable. Click "Visit Official Site" to reach oct-clinicaltrials.com directly.